Cervomed Inc (CRVO)

$3.11 -0.03 (-0.96%)
Market Cap 28.80M
Revenue (ttm) 4.01M
Net Income (ttm) -26.97M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -672.57%
Debt to Equity Ratio 0.00
Volume 75,400
Avg Vol 51,402
Day's Range N/A - N/A
Shares Out 9.26M
Stochastic %K 50%
Beta -0.63
Analysts Strong Sell
Price Target $22.00

Company Profile

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatmen...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 744 4400
Address:
20 Park Plaza, Suite 424, Boston, United States
BPler
BPler May. 29 at 8:15 AM
$CRVO Just a neutral share in connex with recent death of Ted Turner: Highlights why there is not only a huge need (second most common form of progressive dementia) for drugs to fight and maybe reverse effects from LDB, there is also a lack of current good medication option with other dementia meds (which makes the data from Neflamapimod even more impressive regarding med tolerance) "The reason for this, Loeb explained, is that individuals with LBD are extremely sensitive to medications. "The wrong drugs − particularly older antipsychotics − can add to or create hallucinations and can contribute to a much worsened, dangerous condition," Loeb said." (Source: Norma Loeb, the founder of the Lewy Body Dementia Resource Center, https://eu.usatoday.com/story/life/health-wellness/2026/05/06/lewy-body-dementia-explainer/89890433007/)
0 · Reply
BPler
BPler May. 28 at 8:44 AM
$CRVO https://www.theglobeandmail.com/investing/markets/stocks/ONCY/pressreleases/2146909/analysts-offer-insights-on-healthcare-companies-cervomed-crvo-bicara-therapeutics-inc-bcax-and-oncolytics-biotech-oncy/ CervoMed (CRVO) H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on CervoMed today and set a price target of $25.00. The company’s shares closed last Friday at $3.06, close to its 52-week low of $1.80. According to TipRanks.com, Selvaraju is a 5-star analyst with an average return of 22.1% and a 52.7% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Santhera Pharmaceuticals Holding, MoonLake Immunotherapeutics, and Aardvark Therapeutics, Inc. ;'> CervoMed has an analyst consensus of Strong Buy, with a price target consensus of $20.40, which is a 549.7% upside from current levels. In a report issued on May 18, JonesTrading also maintained a Buy rating on the stock with a $20.00 price target.
1 · Reply
MistCircuit70
MistCircuit70 May. 27 at 11:35 PM
$CRVO RSI moves above 55–60 and holds for more!!
0 · Reply
BadPickle2105
BadPickle2105 May. 27 at 9:13 PM
$CRVO count my blessings every day for getting outta here at $9
0 · Reply
SuperGreenToday
SuperGreenToday May. 27 at 3:24 PM
$CRVO
0 · Reply
Masonic11
Masonic11 May. 22 at 11:12 PM
$CRVO So, what's the friggn deal here??? I lost my ass with Diffusion Pharmaceuticals RS. Then merger here. Did their technology fizzle out?? I got pissed off and stopped following. After a 30k loss. Someone tell me why I should put another 30k here. Not passive FUD, truth. What's near term biotech catalysts??
1 · Reply
steven1x
steven1x May. 22 at 7:47 PM
$CRVO funding? https://g.co/gemini/share/bebef1793abb
1 · Reply
generaltom
generaltom May. 21 at 12:55 PM
$CRVO would Boger still be on the board if he thought this was going to fail I wonder sometimes
1 · Reply
LowCountryHooker
LowCountryHooker May. 20 at 10:09 PM
$CRVO
0 · Reply
generaltom
generaltom May. 20 at 6:31 PM
$CGTX Always find it odd that $CRVO has so many more watchers than CGTX. I’m in both but CGTX is definitely worth a few watchers
1 · Reply
Latest News on CRVO
CervoMed price target lowered to $9 from $11 at Roth Capital

2026-05-18T21:35:08.000Z - 12 days ago

CervoMed price target lowered to $9 from $11 at Roth Capital

CervoMed Reports First Quarter 2026 Financial Results and Provides Corporate Updates

May 18, 2026, 7:30 AM EDT - 12 days ago

CervoMed Reports First Quarter 2026 Financial Results and Provides Corporate Updates

CervoMed Quarterly report: Q1 2026

May 15, 2026, 7:00 AM EDT - 15 days ago

CervoMed Quarterly report: Q1 2026

CervoMed Earnings release: Q1 2026

May 15, 2026, 7:00 AM EDT - 15 days ago

CervoMed Earnings release: Q1 2026

CervoMed Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 4 weeks ago

CervoMed Proxy statement: Proxy filing

CervoMed presents neflamapimod MRI data

2026-04-22T14:32:59.000Z - 5 weeks ago

CervoMed presents neflamapimod MRI data

CervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies

Apr 22, 2026, 7:30 AM EDT - 5 weeks ago

CervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies

CervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting

Apr 7, 2026, 7:30 AM EDT - 7 weeks ago

CervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting

CervoMed Transcript: The 38th Annual Roth Conference

Mar 23, 2026, 3:00 PM EDT - 2 months ago

CervoMed Transcript: The 38th Annual Roth Conference

CervoMed Slides: The 38th Annual Roth Conference

Mar 23, 2026, 3:00 PM EDT - 2 months ago

CervoMed Slides: The 38th Annual Roth Conference

CervoMed’s neflamapimod shows efficacy in dementia with DLB

2026-03-19T11:56:17.000Z - 2 months ago

CervoMed’s neflamapimod shows efficacy in dementia with DLB

CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod's Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer's Disease Co-Pathology

Mar 19, 2026, 7:30 AM EDT - 2 months ago

CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod's Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer's Disease Co-Pathology

CervoMed price target lowered to $11 from $19 at Roth Capital

2026-03-17T23:00:26.000Z - 2 months ago

CervoMed price target lowered to $11 from $19 at Roth Capital

CervoMed price target raised to $21 from $15 at Chardan

2026-03-17T22:25:46.000Z - 2 months ago

CervoMed price target raised to $21 from $15 at Chardan

CervoMed Earnings release: Q4 2025

Mar 17, 2026, 4:00 PM EDT - 2 months ago

CervoMed Earnings release: Q4 2025

CervoMed Annual report: Q4 2025

Mar 17, 2026, 4:00 PM EDT - 2 months ago

CervoMed Annual report: Q4 2025

CervoMed reports Q4 revenue $4.M vs. $9.7M in 2024

2026-03-17T11:46:53.000Z - 2 months ago

CervoMed reports Q4 revenue $4.M vs. $9.7M in 2024

CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates

Mar 17, 2026, 7:30 AM EDT - 2 months ago

CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates

CervoMed Slides: Corporate presentation

Mar 17, 2026, 7:00 AM EDT - 2 months ago

CervoMed Slides: Corporate presentation

CervoMed announces presentations at AP/PD 2026 scientific conference

2026-03-12T11:27:04.000Z - 2 months ago

CervoMed announces presentations at AP/PD 2026 scientific conference

CervoMed completes Phase 1 volunteer study for neflamapimod

2026-03-04T12:41:24.000Z - 3 months ago

CervoMed completes Phase 1 volunteer study for neflamapimod

CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies

Mar 4, 2026, 7:30 AM EST - 3 months ago

CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies

CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform

2026-02-18T11:16:19.000Z - 3 months ago

CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform

CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors

Feb 17, 2026, 8:00 AM EST - 3 months ago

CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors

SCYX

CervoMed initiated with an Overweight at Cantor Fitzgerald

2025-12-18T11:40:57.000Z - 5 months ago

CervoMed initiated with an Overweight at Cantor Fitzgerald

CervoMed’s neflamapimod shows efficacy in slowing dementia

2025-12-04T22:05:45.000Z - 6 months ago

CervoMed’s neflamapimod shows efficacy in slowing dementia

CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies

Dec 4, 2025, 5:00 PM EST - 6 months ago

CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies

CervoMed presents new data from Phase 2b RewinD-LB trial on neflamapimod

2025-12-02T12:11:05.000Z - 6 months ago

CervoMed presents new data from Phase 2b RewinD-LB trial on neflamapimod

CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)

Dec 2, 2025, 7:00 AM EST - 6 months ago

CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)

CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference

Nov 24, 2025, 7:00 AM EST - 6 months ago

CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference

CervoMed price target lowered to $19 from $20 at Roth Capital

2025-11-10T19:35:22.000Z - 7 months ago

CervoMed price target lowered to $19 from $20 at Roth Capital

CervoMed reports Q3 EPS (84c), consensus (56c)

2025-11-10T12:11:54.000Z - 7 months ago

CervoMed reports Q3 EPS (84c), consensus (56c)

CervoMed Earnings release: Q3 2025

Nov 7, 2025, 7:00 AM EST - 7 months ago

CervoMed Earnings release: Q3 2025

CervoMed Quarterly report: Q3 2025

Nov 7, 2025, 7:00 AM EST - 7 months ago

CervoMed Quarterly report: Q3 2025

CervoMed upgraded to Buy from Neutral at H.C. Wainwright

2025-11-05T11:15:32.000Z - 7 months ago

CervoMed upgraded to Buy from Neutral at H.C. Wainwright

CervoMed announces FDA alignment on neflamapimod registration path

2025-11-04T12:41:55.000Z - 7 months ago

CervoMed announces FDA alignment on neflamapimod registration path

CervoMed appoints Quigley to board of directors

2025-10-28T12:31:51.000Z - 7 months ago

CervoMed appoints Quigley to board of directors

CervoMed Transcript: Emerging Growth Conference

Oct 22, 2025, 11:25 AM EDT - 7 months ago

CervoMed Transcript: Emerging Growth Conference

CervoMed to Present at the Emerging Growth Conference

Oct 20, 2025, 8:00 AM EDT - 7 months ago

CervoMed to Present at the Emerging Growth Conference

CervoMed price target raised to $20 from $16 at Roth Capital

2025-10-17T10:31:09.000Z - 8 months ago

CervoMed price target raised to $20 from $16 at Roth Capital

CervoMed announce new data from Phase 2b trial of RewinD-LB

2025-10-08T11:05:49.000Z - 8 months ago

CervoMed announce new data from Phase 2b trial of RewinD-LB

CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies

Oct 8, 2025, 7:00 AM EDT - 8 months ago

CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies

CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

Oct 2, 2025, 8:00 AM EDT - 8 months ago

CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

CervoMed Highlights Neflamapimod's Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association Conference

Sep 17, 2025, 7:30 AM EDT - 9 months ago

CervoMed Highlights Neflamapimod's Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association Conference

CervoMed Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 2:00 PM EDT - 9 months ago

CervoMed Transcript: H.C. Wainwright 27th Annual Global Investment Conference

CervoMed to Participate in Upcoming Investor Conferences

Sep 3, 2025, 8:00 AM EDT - 9 months ago

CervoMed to Participate in Upcoming Investor Conferences

CervoMed Earnings release: Q2 2025

Aug 8, 2025, 4:00 PM EDT - 10 months ago

CervoMed Earnings release: Q2 2025

CervoMed Quarterly report: Q2 2025

Aug 8, 2025, 4:00 PM EDT - 10 months ago

CervoMed Quarterly report: Q2 2025

CervoMed Transcript: Status Update

Jul 28, 2025, 8:00 AM EDT - 10 months ago

CervoMed Transcript: Status Update

CervoMed Press release: Status Update

Jul 28, 2025, 8:00 AM EDT - 10 months ago

CervoMed Press release: Status Update

CervoMed Slides: Status Update

Jul 28, 2025, 8:00 AM EDT - 10 months ago

CervoMed Slides: Status Update

CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod's Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration

Jul 28, 2025, 7:00 AM EDT - 10 months ago

CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod's Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration

CervoMed Announces Late-Breaking Presentations at Alzheimer's Association® International Congress 2025

Jul 8, 2025, 7:00 AM EDT - 11 months ago

CervoMed Announces Late-Breaking Presentations at Alzheimer's Association® International Congress 2025

CervoMed Slides: Corporate Presentation

Jun 25, 2025, 7:00 AM EDT - 1 year ago

CervoMed Slides: Corporate Presentation

CervoMed Slides: Corporate Presentation

May 28, 2025, 7:00 AM EDT - 1 year ago

CervoMed Slides: Corporate Presentation

CervoMed Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 20, 2025, 5:00 PM EDT - 1 year ago

CervoMed Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

CervoMed Earnings release: Q1 2025

May 12, 2025, 9:30 AM EDT - 1 year ago

CervoMed Earnings release: Q1 2025

CervoMed Quarterly report: Q1 2025

May 12, 2025, 9:30 AM EDT - 1 year ago

CervoMed Quarterly report: Q1 2025

CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates

May 12, 2025, 8:00 AM EDT - 1 year ago

CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates

CervoMed Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

CervoMed Proxy statement: Proxy Filing

CervoMed Slides: Investor Presentation

Apr 5, 2025, 7:00 AM EDT - 1 year ago

CervoMed Slides: Investor Presentation

CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™)

Mar 25, 2025, 8:00 AM EDT - 1 year ago

CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™)

CervoMed Earnings release: Q4 2024

Mar 18, 2025, 4:00 PM EDT - 1 year ago

CervoMed Earnings release: Q4 2024

CervoMed Annual report: Q4 2024

Mar 18, 2025, 4:00 PM EDT - 1 year ago

CervoMed Annual report: Q4 2024

CervoMed Slides: Investor Presentation

Mar 11, 2025, 8:00 AM EDT - 1 year ago

CervoMed Slides: Investor Presentation

CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies

Mar 10, 2025, 4:05 PM EDT - 1 year ago

CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies

CervoMed Slides: Investor Presentation

Jan 31, 2025, 7:00 AM EST - 1 year ago

CervoMed Slides: Investor Presentation

CervoMed to Present at the 8th International Lewy Body Dementia Conference

Jan 29, 2025, 8:00 AM EST - 1 year ago

CervoMed to Present at the 8th International Lewy Body Dementia Conference

CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 12, 2024, 7:00 AM EST - 1 year ago

CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CervoMed's stock craters 77% after failed trial of treatment for rare brain disease

Dec 10, 2024, 10:10 AM EST - 1 year ago

CervoMed's stock craters 77% after failed trial of treatment for rare brain disease

CervoMed's dementia drug fails to meet mid-stage trial goals

Dec 10, 2024, 7:33 AM EST - 1 year ago

CervoMed's dementia drug fails to meet mid-stage trial goals

CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies

Dec 10, 2024, 7:00 AM EST - 1 year ago

CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies

CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia

Nov 27, 2024, 7:00 AM EST - 1 year ago

CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia

CervoMed Transcript: Stifel 2024 Healthcare Conference

Nov 19, 2024, 3:00 PM EST - 1 year ago

CervoMed Transcript: Stifel 2024 Healthcare Conference

CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Nov 12, 2024, 7:00 AM EST - 1 year ago

CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

CervoMed Quarterly report: Q3 2024

Nov 12, 2024, 7:00 AM EST - 1 year ago

CervoMed Quarterly report: Q3 2024

CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup

Nov 8, 2024, 9:55 AM EST - 1 year ago

CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup

CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

Nov 4, 2024, 8:00 AM EST - 1 year ago

CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference

Oct 29, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference

CervoMed Registration statement: Registration Filing

Oct 3, 2024, 8:00 AM EDT - 1 year ago

CervoMed Registration statement: Registration Filing

CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference

Oct 2, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference

CervoMed Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Sep 6, 2024, 1:50 PM EDT - 1 year ago

CervoMed Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies

Aug 22, 2024, 8:00 AM EDT - 1 year ago

CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies

CervoMed Transcript: Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024

Aug 13, 2024, 12:30 PM EDT - 1 year ago

CervoMed Transcript: Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024

CervoMed Quarterly report: Q2 2024

Aug 12, 2024, 4:00 PM EDT - 1 year ago

CervoMed Quarterly report: Q2 2024

CervoMed Earnings release: Q2 2024

Aug 12, 2024, 4:00 PM EDT - 1 year ago

CervoMed Earnings release: Q2 2024

CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference

Jul 30, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference

CervoMed Transcript: Status Update

Jul 23, 2024, 10:00 AM EDT - 2 years ago

CervoMed Transcript: Status Update

CervoMed Slides: Corporate Presentation

Jul 22, 2024, 8:00 AM EDT - 2 years ago

CervoMed Slides: Corporate Presentation

CervoMed to Participate in the Emerging Growth Conference

Jul 17, 2024, 8:00 AM EDT - 2 years ago

CervoMed to Participate in the Emerging Growth Conference

CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024

Jul 11, 2024, 8:51 AM EDT - 2 years ago

CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024

CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies

Jun 11, 2024, 8:00 AM EDT - 2 years ago

CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies

CervoMed Registration statement: Registration Filing

May 30, 2024, 8:00 AM EDT - 2 years ago

CervoMed Registration statement: Registration Filing

CervoMed to Appoint William Elder as Chief Financial Officer

May 20, 2024, 8:00 AM EDT - 2 years ago

CervoMed to Appoint William Elder as Chief Financial Officer

CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates

May 15, 2024, 8:00 AM EDT - 2 years ago

CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates

CervoMed Quarterly report: Q1 2024

May 14, 2024, 6:00 PM EDT - 2 years ago

CervoMed Quarterly report: Q1 2024

CervoMed Earnings release: Q1 2024

May 14, 2024, 6:00 PM EDT - 2 years ago

CervoMed Earnings release: Q1 2024

CervoMed Registration statement: Registration Filing

May 10, 2024, 8:00 AM EDT - 2 years ago

CervoMed Registration statement: Registration Filing

CervoMed Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

CervoMed Proxy statement: Proxy Filing

CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

Apr 1, 2024, 8:00 AM EDT - 2 years ago

CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

CervoMed Earnings release: Q4 2023

Apr 1, 2024, 7:00 AM EDT - 2 years ago

CervoMed Earnings release: Q4 2023

CervoMed Annual report: Q4 2023

Apr 1, 2024, 7:00 AM EDT - 2 years ago

CervoMed Annual report: Q4 2023

CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors

Mar 28, 2024, 8:30 AM EDT - 2 years ago

CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors

CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024

Mar 5, 2024, 8:00 AM EST - 2 years ago

CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024

CervoMed to Participate in the BIO CEO and Investor Conference

Feb 21, 2024, 8:00 AM EST - 2 years ago

CervoMed to Participate in the BIO CEO and Investor Conference

CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies

Feb 12, 2024, 8:00 AM EST - 2 years ago

CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies

CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board

Feb 7, 2024, 8:30 AM EST - 2 years ago

CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board

CervoMed to Participate in the Emerging Growth Conference 67

Feb 5, 2024, 8:00 AM EST - 2 years ago

CervoMed to Participate in the Emerging Growth Conference 67

CervoMed to Participate in the Emerging Growth Conference 66

Jan 5, 2024, 8:00 AM EST - 2 years ago

CervoMed to Participate in the Emerging Growth Conference 66

CervoMed Reports Third Quarter 2023 Financial Results and Business Highlights

Nov 13, 2023, 7:00 AM EST - 2 years ago

CervoMed Reports Third Quarter 2023 Financial Results and Business Highlights

CervoMed Quarterly report: Q3 2023

Nov 13, 2023, 7:00 AM EST - 2 years ago

CervoMed Quarterly report: Q3 2023

CervoMed Earnings release: Q3 2023

Nov 13, 2023, 7:00 AM EST - 2 years ago

CervoMed Earnings release: Q3 2023

CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Learnings from Phase 2a Which Optimized the Design of the Phase 2b Clinical Study of Neflamapimod in Dementia with Lewy Bodies

Oct 25, 2023, 2:50 PM EDT - 2 years ago

CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Learnings from Phase 2a Which Optimized the Design of the Phase 2b Clinical Study of Neflamapimod in Dementia with Lewy Bodies

CervoMed Announces Publications in Major Peer-Reviewed Journals That Inform on Potential of Neflamapimod as a Disease-Modifying Therapy for the Major Dementias

Oct 24, 2023, 7:00 AM EDT - 2 years ago

CervoMed Announces Publications in Major Peer-Reviewed Journals That Inform on Potential of Neflamapimod as a Disease-Modifying Therapy for the Major Dementias

CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Phase 2b Neflamapimod Program for the Treatment of Patients with Dementia with Lewy Bodies

Oct 18, 2023, 7:00 AM EDT - 2 years ago

CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Phase 2b Neflamapimod Program for the Treatment of Patients with Dementia with Lewy Bodies

BPler
BPler May. 29 at 8:15 AM
$CRVO Just a neutral share in connex with recent death of Ted Turner: Highlights why there is not only a huge need (second most common form of progressive dementia) for drugs to fight and maybe reverse effects from LDB, there is also a lack of current good medication option with other dementia meds (which makes the data from Neflamapimod even more impressive regarding med tolerance) "The reason for this, Loeb explained, is that individuals with LBD are extremely sensitive to medications. "The wrong drugs − particularly older antipsychotics − can add to or create hallucinations and can contribute to a much worsened, dangerous condition," Loeb said." (Source: Norma Loeb, the founder of the Lewy Body Dementia Resource Center, https://eu.usatoday.com/story/life/health-wellness/2026/05/06/lewy-body-dementia-explainer/89890433007/)
0 · Reply
BPler
BPler May. 28 at 8:44 AM
$CRVO https://www.theglobeandmail.com/investing/markets/stocks/ONCY/pressreleases/2146909/analysts-offer-insights-on-healthcare-companies-cervomed-crvo-bicara-therapeutics-inc-bcax-and-oncolytics-biotech-oncy/ CervoMed (CRVO) H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on CervoMed today and set a price target of $25.00. The company’s shares closed last Friday at $3.06, close to its 52-week low of $1.80. According to TipRanks.com, Selvaraju is a 5-star analyst with an average return of 22.1% and a 52.7% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Santhera Pharmaceuticals Holding, MoonLake Immunotherapeutics, and Aardvark Therapeutics, Inc. ;'> CervoMed has an analyst consensus of Strong Buy, with a price target consensus of $20.40, which is a 549.7% upside from current levels. In a report issued on May 18, JonesTrading also maintained a Buy rating on the stock with a $20.00 price target.
1 · Reply
MistCircuit70
MistCircuit70 May. 27 at 11:35 PM
$CRVO RSI moves above 55–60 and holds for more!!
0 · Reply
BadPickle2105
BadPickle2105 May. 27 at 9:13 PM
$CRVO count my blessings every day for getting outta here at $9
0 · Reply
SuperGreenToday
SuperGreenToday May. 27 at 3:24 PM
$CRVO
0 · Reply
Masonic11
Masonic11 May. 22 at 11:12 PM
$CRVO So, what's the friggn deal here??? I lost my ass with Diffusion Pharmaceuticals RS. Then merger here. Did their technology fizzle out?? I got pissed off and stopped following. After a 30k loss. Someone tell me why I should put another 30k here. Not passive FUD, truth. What's near term biotech catalysts??
1 · Reply
steven1x
steven1x May. 22 at 7:47 PM
$CRVO funding? https://g.co/gemini/share/bebef1793abb
1 · Reply
generaltom
generaltom May. 21 at 12:55 PM
$CRVO would Boger still be on the board if he thought this was going to fail I wonder sometimes
1 · Reply
LowCountryHooker
LowCountryHooker May. 20 at 10:09 PM
$CRVO
0 · Reply
generaltom
generaltom May. 20 at 6:31 PM
$CGTX Always find it odd that $CRVO has so many more watchers than CGTX. I’m in both but CGTX is definitely worth a few watchers
1 · Reply
jalal81
jalal81 May. 19 at 9:16 PM
$CRVO know what you own
0 · Reply
BPler
BPler May. 19 at 3:24 PM
$CRVO RA Capital Management is beneficial owner and had nearly 100 Mio. ready to buy more with the warrant options. Morgan Stanley was involved in the brokering of that private placement and is now also a beneficial owner. Not sure what they know what we don't know, but at least there is not a visible pullback of beneficial owners and previous investors. PS And of course I would have rather bought in now than in the past but there was not crystal ball available and the safest play in my mind was to stay long and keep adding.
0 · Reply
LowCountryHooker
LowCountryHooker May. 19 at 2:17 AM
$CRVO if you chose this as your pick and feel, you have made the wrong decision, you are mistaken. You just have the wrong strategy.
0 · Reply
LowCountryHooker
LowCountryHooker May. 19 at 2:16 AM
$CRVO longevity prevails! It’s still a win-win, depending on the fortitude of your constitution.
0 · Reply
LowCountryHooker
LowCountryHooker May. 18 at 11:37 PM
$CRVO make it or break it. Had to grab another 500 at this price and average down. At this point, unfortunately I’m committed. After seven years, there’s not much choice. I believe in what we have. Worst case scenario I have to keep buying until we get bought out or some BP buys in.
1 · Reply
focafoca99
focafoca99 May. 18 at 9:25 PM
$CRVO released its cash runway update, saying $12.9 million cash will fund operations through September 2026. https://www.rapidticker.com/news/crvo-sec-filing-f7135e
0 · Reply
Messerschmittbf109
Messerschmittbf109 May. 18 at 5:52 PM
$CRVO bla bla bla bla
0 · Reply
Doki0926
Doki0926 May. 18 at 4:56 PM
$CRVO today I quit
0 · Reply
BPler
BPler May. 18 at 3:50 PM
$CRVO Not sure why the cryers just don't short or sell it. But Vanguard Capital disclosed on Friday that they have bought in with over 310.000 shares. https://fintel.com.de/so/us/crvo/vanguard-capital-management-llc-7556
2 · Reply
Stu_padasso
Stu_padasso May. 18 at 2:49 PM
$CRVO well fucked everyone again. financing after hpurs? how bad
1 · Reply
Doki0926
Doki0926 May. 18 at 2:32 PM
$CRVO honestly WTF is it going to 0❓❓❓🤡🤡🤡🤡
1 · Reply
BPler
BPler May. 18 at 11:46 AM
$CRVO John Alam, MD, Chief Executive Officer of CervoMed, stated: “CervoMed has built a robust and compelling neflamapimod dataset in patients with dementia with Lewy bodies (DLB) comprised of positive Phase 2b clinical data, including first-ever magnetic resonance imaging (MRI) data showing evidence of increase in size and enhancement of function in the basal forebrain, key accompanying biomarker and PK/PD data, and a new formulation and manufacturing process. Collectively, this work has led to alignment with the United States (US) Food and Drug Administration (FDA) and global regulatory authorities on a final design for our planned Phase 3 trial in patients with DLB. We are extremely proud of the recent progress we have made, and are encouraged by the positive feedback received from various stakeholders around the potential of neflamapimod as a disease-modifying treatment for DLB.” https://www.stocktitan.net/news/CRVO/cervo-med-reports-first-quarter-2026-financial-results-and-provides-dmzyak20m4tb.html
1 · Reply